125 related articles for article (PubMed ID: 21935604)
21. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
22. SNP-SNP interactions between DNA repair genes were associated with breast cancer risk in a Korean population.
Han W; Kim KY; Yang SJ; Noh DY; Kang D; Kwack K
Cancer; 2012 Feb; 118(3):594-602. PubMed ID: 21751184
[TBL] [Abstract][Full Text] [Related]
23. Association of interleukin-10 gene variation with breast cancer prognosis.
Gerger A; Renner W; Langsenlehner T; Hofmann G; Knechtel G; Szkandera J; Samonigg H; Krippl P; Langsenlehner U
Breast Cancer Res Treat; 2010 Feb; 119(3):701-5. PubMed ID: 19437115
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
[TBL] [Abstract][Full Text] [Related]
25. The role of polymorphisms in circadian pathway genes in breast tumorigenesis.
Dai H; Zhang L; Cao M; Song F; Zheng H; Zhu X; Wei Q; Zhang W; Chen K
Breast Cancer Res Treat; 2011 Jun; 127(2):531-40. PubMed ID: 20978934
[TBL] [Abstract][Full Text] [Related]
26. Risk of aggressive breast cancer in women of Han nationality carrying TGFB1 rs1982073 C allele and FGFR2 rs1219648 G allele in North China.
Chen XH; Li XQ; Chen Y; Feng YM
Breast Cancer Res Treat; 2011 Jan; 125(2):575-82. PubMed ID: 20640597
[TBL] [Abstract][Full Text] [Related]
27. Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion.
Jezierska A; Olszewski WP; Pietruszkiewicz J; Olszewski W; Matysiak W; Motyl T
Med Sci Monit; 2006 Jul; 12(7):BR245-56. PubMed ID: 16810131
[TBL] [Abstract][Full Text] [Related]
28. ALCAM--novel multiple sclerosis locus interfering with HLA-DRB1*1501.
Wagner M; Wiśniewski A; Bilińska M; Pokryszko-Dragan A; Nowak I; Kuśnierczyk P; Jasek M
J Neuroimmunol; 2013 May; 258(1-2):71-6. PubMed ID: 23507476
[TBL] [Abstract][Full Text] [Related]
29. Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study.
Deming SL; Ren Z; Wen W; Shu XO; Cai Q; Gao YT; Zheng W
Breast Cancer Res Treat; 2007 Sep; 104(3):309-19. PubMed ID: 17063263
[TBL] [Abstract][Full Text] [Related]
30. Genetic variation in the androgen estrogen conversion pathway in relation to breast cancer prognosticators.
Darabi H; Czene K; Wedrén S; Li Y; Liu J; Hall P; Humphreys K
Breast Cancer Res Treat; 2011 Jun; 127(2):503-9. PubMed ID: 20960227
[TBL] [Abstract][Full Text] [Related]
31. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
[TBL] [Abstract][Full Text] [Related]
32. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
[TBL] [Abstract][Full Text] [Related]
33. Common variation in BRCA2 and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort.
Freedman ML; Penney KL; Stram DO; Le Marchand L; Hirschhorn JN; Kolonel LN; Altshuler D; Henderson BE; Haiman CA
Hum Mol Genet; 2004 Oct; 13(20):2431-41. PubMed ID: 15317758
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.
Choi JY; Lee KM; Park SK; Noh DY; Ahn SH; Chung HW; Han W; Kim JS; Shin SG; Jang IJ; Yoo KY; Hirvonen A; Kang D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1090-5. PubMed ID: 15894657
[TBL] [Abstract][Full Text] [Related]
35. Genetic variants in epigenetic genes and breast cancer risk.
Cebrian A; Pharoah PD; Ahmed S; Ropero S; Fraga MF; Smith PL; Conroy D; Luben R; Perkins B; Easton DF; Dunning AM; Esteller M; Ponder BA
Carcinogenesis; 2006 Aug; 27(8):1661-9. PubMed ID: 16501248
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D receptor variants and breast cancer risk in the Polish population.
Gapska P; Scott RJ; Serrano-Fernandez P; Huzarski T; Byrski T; Kładny J; Gronwald J; Górski B; Cybulski C; Lubinski J; Debniak T
Breast Cancer Res Treat; 2009 Jun; 115(3):629-33. PubMed ID: 18587672
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.
Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823
[TBL] [Abstract][Full Text] [Related]
38. Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Mol Carcinog; 2010 Jun; 49(6):545-55. PubMed ID: 20306497
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women.
Suter NM; Malone KE; Daling JR; Doody DR; Ostrander EA
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):127-35. PubMed ID: 12582022
[TBL] [Abstract][Full Text] [Related]
40. Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?
Jakubowska A; Jaworska K; Cybulski C; Janicka A; Szymańska-Pasternak J; Lener M; Narod SA; Lubiński J;
Eur J Cancer; 2009 Mar; 45(5):837-42. PubMed ID: 19071013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
